05.20.08
Oso Biopharmaceuticals Manufacturing, LLC has purchased the Albuquerque, NM-based sterile injectables manufacturing business of Catalent Pharma Solutions. Terms of the transaction were not disclosed.
The unit provides cGMP glass vial filling and lyophilization services for injectable drugs and biologics for both commercial and clinical projects. Oso Biopharmaceuticals will retain all employees associated with the business and continue to serve existing the unit's customers in North America and Europe.
Dr. Stuart Rose, chief executive officer and president of Oso Biopharmaceuticals, said, “We are delighted to have been successful in acquiring Catalent's sterile injectables business based in Albuquerque. It fits exceedingly well with our strategy to build a world class, high quality contract manufacturing company. We will work tirelessly with the talent pool in Albuquerque to meet the highest demands and expectations of our global customer base.”
Richard Yarwood, group president of sterile technologies for Catalent, said, “We are pleased to have completed this planned step in the evolution of our Sterile Technologies business. We are also pleased that Oso Biopharmaceuticals has acquired this business, as we expect they will continue to provide the facility’s customers the high degree of quality and compliance they have received in the past. We also appreciate the commitment Oso Biopharmaceuticals has demonstrated to the future of the business, and to the dedicated employees at the site.”
The unit provides cGMP glass vial filling and lyophilization services for injectable drugs and biologics for both commercial and clinical projects. Oso Biopharmaceuticals will retain all employees associated with the business and continue to serve existing the unit's customers in North America and Europe.
Dr. Stuart Rose, chief executive officer and president of Oso Biopharmaceuticals, said, “We are delighted to have been successful in acquiring Catalent's sterile injectables business based in Albuquerque. It fits exceedingly well with our strategy to build a world class, high quality contract manufacturing company. We will work tirelessly with the talent pool in Albuquerque to meet the highest demands and expectations of our global customer base.”
Richard Yarwood, group president of sterile technologies for Catalent, said, “We are pleased to have completed this planned step in the evolution of our Sterile Technologies business. We are also pleased that Oso Biopharmaceuticals has acquired this business, as we expect they will continue to provide the facility’s customers the high degree of quality and compliance they have received in the past. We also appreciate the commitment Oso Biopharmaceuticals has demonstrated to the future of the business, and to the dedicated employees at the site.”